Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks

Clinical Cancer Research

Volumn 4, Issue 9, 1998, Pages 2111-2117

  Alberts, Steven R ^a   Erlichman, Charles ^a   Reid, Joel M ^a   Sloan, Jeff A ^a   Ames, Matthew M ^a   Richardson, Ronald L ^a   Goldberg, Richard M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; DUOCARMYCIN B2; PIBROZELESIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DISTRIBUTION; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PYRROLIDINONES;

EID: 0031667354     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ichimura, M., Ogawa, T., Takahashi, K-I., Kobayashi, E., Kawamoto, I., Yasuzawa, T., Takahashi, I., and Nakano, H. Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp. J. Antibiot. (Tokyo), 43: 1037-1038, 1990.
2. Ichimura, M., Ogawa, T., Katsumata, S., Takahashi, K-I., Takahashi, I., and Nakano, H. Duocarmycins, new antitumor antibiotics produced by Streptomyces; producing organisms and improved production. J. Antibiot. (Tokyo), 44: 1045-1053, 1991.
3. 2. J. Antibiot. (Tokyo), 42: 1299-1301, 1989.
4. Takahashi, I., Takahashi, K-I., Ichimura, M., Morimoto, M., Asano, K., Kawamoto, I., Tomita, F., and Nakano, H. Duocarmycin A, a new antitumor antibiotic from Streptomyces. J. Antibiot. (Tokyo), 41: 1915-1917, 1988.
5. Boger, D. L., and Johnson, D. S. CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc. Natl. Acad. Sci. USA, 92: 3642-3649, 1995.
6. Hurley, L. H., Reynolds, V. L., Swenson, D. H., Petzold, G. L., and Scahill, T. A. Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science (Washington DC), 226: 843-844, 1984.
7. Bhuyan, B. K., Smith, K. S., Adams, E. G., Wallace, T. L., Von Hoff, D. D., and Li, L. H. Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects. Cancer Chemother. Pharmacol., 30: 348-354, 1992.
8. Li, L. H., DeKoning, T. F., Kelly, R. C., Krueger, W. C., McGovern, J. P., Padbury, G. E., Petzold, G. L., Wallace, T. L., Ouding, R. J., Prairie, M. D., and Gebhard, I. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrrolindole analogue. Cancer Res., 52: 4904-4913, 1992.
9. 3 cells treated with duocarmycins or other antitumor agents by pulse field gel electrophoresis. Jpn. J. Cancer Res., 84: 93-98, 1993.
10. Gomi, K., Kobayashi, E., Miyoshi, K., Ashizawa, T., Okamoto, A., Ogawa, T., Katsumata, S., Mihara, A., Okabe, M., and Hirata, T. Anticellular and antitumor activity of duocarmycins, novel antitumor antibiotics. Jpn. J. Cancer Res., 83: 113-120, 1992.
11. Nagamura, S., Kanda, Y., Kobayashi, E., Gomi, K., and Saito, H. Synthesis and antitumor activity of duocarmycin derivatives. Chem. Pharmacol. Bull., 43: 1530-1535, 1995.
12. Yasuzawa, T., Muroi, K-I., Ichimura, M., Takahashi, I., Ogawa, T., Takahashi, K., Sano, H., and Saitoh, Y. Duocarmycins, potent antitumor antibiotics produced by Streptomyces sp.: stractures and chemistry. Chem. Pharmacol. Bull., 43: 378-391, 1995.
13. Kobayashi, E., Okamoto, A., Asada, M., Okabe, M., Nagamura, S., Asai, A., Saito, H., Gomi, K., and Hirata, T. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Cancer Res., 54: 2404-2410, 1994.
14. Ogasawara, H., Nishio, K., Kanzawa, F., Lee, Y-S., Funayama, Y., Ohira, T., Kuraishi, Y., Isogai, Y., and Saijo, N. Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn. J. Cancer Res., 86: 124-129, 1995.
15. Asai, A., Nagamura, S., and Saito, H. A novel property of duocarmycin and its analogues for covalent reaction with DNA. J. Am. Chem. Soc., 116: 4171-4177, 1994.
16. Nagamura, S., Kobayashi, E., Gomi, K., and Saito, H. Studies on the active metabolite (DU-86) of KW-2189, a novel derivative of duocarmycin. Bioorg. Med. Chem., 6: 2147-2150, 1996.
17. 3 cells. Jpn. J. Cancer Res., 85: 1304-1311, 1994.
18. Ogasawara, H., Nishio, K., Takeda, Y., Ohmori, T., Kubota, N., Funayama, Y., Ohira, T., Kuraishi, Y., Isogai, Y., and Saijo, N. A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces strand breaks in human small cell lung cancer cells. Jpn. J. Cancer Res., 85: 418-425, 1994.
19. Bhuyan, B. K., Crampton, S. L., and Adams, E. G. Cell cycle effects of CC-1065. Cancer Res., 43: 4227-4232, 1983.
20. Fleming, G. F., Ratain, M. J., O'Brien, S. M., Schilsky, R. L., Hoffman, P. C., Richards, J. M., Vogelzang, N. J., Kasunic, D. A., and Earhart, R. H. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J. Natl. Cancer Inst. (Bethesda), 86: 368-372, 1994.
21. Wolff, I., Bench, K., Beijnen, J. H., Bruntsch, U., Cavalli, F., Dejong, J., Groot, Y., Vantellingen, O., Wanders, J., and Sessa, C., for the Early Clinical Studies of the EORTC. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days. Clin. Cancer Res., 2: 1717-1723, 1996.
22. DeVita, V. T., Carbone, P. P., Owens, A. H., Jr., Gold, L., Krant, M. J., and Edmonson, J. Clinical trial with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res., 25: 1876-1881, 1965.
23. Niitani, H., Horikoshi, N., Hasegawa, K., Fukuoka, M., Kudoh, S., and Hino, M. Phase I study of KW-2189, a derivative of new anticancer antibiotic duocarmycin. Proc. Am. Assoc. Cancer Res., 36: A1446, 1995.
24. Abbruzzese, J. L., Madden, T., and Newman, R. A. Phase I clinical and pharmacokinetic trial of KW2189 in patients with solid tumors. Proc. Am. Assoc. Cancer Res., 37: 1138, 1996.
25. Satoh T., Hosokawa, M., Atsumi, R., Suzuki, W., Hakusui, H., and Nagai, E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharmacol. Bull., 17: 662-664, 1994.
26. Senter, P. D., Marquardt, H., Thomas, B. A., Hammock, B. D., Frank, I. S., and Svensson, H. P. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs. Cancer Res., 56: 1471-1474, 1996.
27. Chen, S. F., Rothenberg, M. L., Clark, G., Degen, D., Wajima, M., Barton, D., and Von Hoff, D. D. Human tumor carboxylesterase activity correlates with CPT-11 cytotoxicity in vitro. Proc. Am. Assoc. Cancer Res., 35: A2174, 1994.